|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalRegion
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:approvalYear
|
2017-10-31
|
|
gptkbp:ATCCode
|
L01EL13
|
|
gptkbp:brand
|
gptkb:Calquence
|
|
gptkbp:CASNumber
|
1420477-60-6
|
|
gptkbp:chemicalFormula
|
C26H23N7O2
|
|
gptkbp:clinicalTrialPhase
|
gptkb:ASCEND
gptkb:ELEVATE-TN
ACE-LY-004
|
|
gptkbp:contraindication
|
hypersensitivity to acalabrutinib
|
|
gptkbp:drugClass
|
Bruton tyrosine kinase inhibitor
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:genericName
|
gptkb:acalabrutinib
|
|
gptkbp:halfLife
|
1-2 hours
|
|
gptkbp:hasBoxedWarning
|
none
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Calquence
|
|
gptkbp:indication
|
gptkb:mantle_cell_lymphoma
gptkb:small_lymphocytic_lymphoma
chronic lymphocytic leukemia
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:AstraZeneca
|
|
gptkbp:mechanismOfAction
|
Bruton tyrosine kinase inhibitor
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescriptionRequired
|
https://www.azpicentral.com/calquence/calquence.pdf
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
diarrhea
fatigue
headache
neutropenia
thrombocytopenia
|
|
gptkbp:bfsParent
|
gptkb:AstraZeneca
|
|
gptkbp:bfsLayer
|
5
|